Edwards Lifesciences (EW) Cash from Investing Activities (2009 - 2026)

Edwards Lifesciences' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$92.8 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 208.79% year-over-year to -$92.8 million in Q1 2026; TTM through Mar 2026 was -$891.0 million, a 138.16% decrease from a year earlier, with the FY2025 full-year figure at -$712.9 million, down 130.82% from the prior year.
• Cash from Investing Activities improved to -$92.8 million in Q1 2026 per EW's latest filing, from -$198.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $2.7 billion in Q3 2024 and bottomed at -$576.7 million in Q4 2024.
• The 5-year median for Cash from Investing Activities is $63.1 million (2024), against an average of $113.7 million.
• Biggest YoY gain for Cash from Investing Activities was 12520.0% in 2024; the steepest drop was 4190.07% in 2024.
• Year by year, Cash from Investing Activities stood at $94.7 million in 2022, then sank by 85.11% to $14.1 million in 2023, then tumbled by 4190.07% to -$576.7 million in 2024, then surged by 65.61% to -$198.3 million in 2025, then surged by 53.2% to -$92.8 million in 2026.
• Per Business Quant, the three latest EW Cash from Investing Activities figures stand at -$92.8 million (Q1 2026), -$198.3 million (Q4 2025), and -$427.8 million (Q3 2025).